Therapeutic effects of cholesterol absorption inhibitor on renal function in patients with chronic kidney disease

Therapeutic effects of cholesterol absorption inhibitor on renal function in patients with chronic kidney disease - Therapeutic effects of cholesterol absorption inhibitor on renal function in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002528

Enrollment

Registered

2009-09-18

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease Hypercholesterolemia

Interventions

Ezetimib 10 mg once daily is administerd as a additive medicine for lipid-lowering therapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease LDL-C > or= 120mg/dl

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity to ezechimibe 2. Dialysis patients 3. Severe liver disease 4. Secondary or drug-induced hypercholesterolemia 5. Pregnant or nursing women or women suspect of pregnancy 6. Judged as inappropriate for study by doctor

Design outcomes

Primary

Measure	Time frame
1) Lipid profile including T-cho, LDL-C, HDL-C, TG, and RLP-C. 2) eFGR 3) Urinary albumin excretion	—

Secondary

Measure	Time frame
1) Glucose profile including FPG, HbA1C, and IRI. 2) Markers of cholesterol synthesis and absorption 3) Markers of oxidative stress including pentosidine and L-FABP 4) CBC and biochemistry including AST, ALT, gammaGTP, BUN, sCr, K, BNP 5) Adverse events	—

Countries

Japan

Contacts

Public ContactKouichi Tamura

Yokohama City University School of Medicine Department of Cardiorenal Medicine

tamukou@med.yokohama-cu.ac.jp045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026